Clinical · Molecular biology · Bioinfo & AI
Artificial intelligence-based diagnostic model for identifying PTPRZ1-MET fusion in a clinically defined secondary glioblastoma cohort
This study analyzed 159 patients with secondary glioblastoma (sGBM) and confirmed that the PTPRZ1-MET fusion is a recurrent oncogenic driver associated with significantly shorter overall and progression-free survival. Researchers identified 359 upregulated genes in fusion-positive tumors, enriched in cell-cycle regulation pathways. An artificial intelligence-based diagnostic model, utilizing a three-gene panel (MET, PCDHGA3, FAM3C), was developed and validated to identify this fusion. This robust molecular signature could facilitate the identification and stratification of sGBM patients positive for the PTPRZ1-MET fusion.